Esperion has had a rocky road to approval for its LDL-cholesterol-lowering drug Nexletol after a late-stage trial in 2018 threatened to derail its quest. But after backing its drug up with strong safety data, Esperion has the green light to
read moreTeva CEO Kåre Schultz has taken the company through a dramatic restructuring aimed at better positioning the company for the future. In an interview with Israel’s Calcalist, he shared details of his approach to the turnaround. More: 'Boring is good,'
read moreSales of Puma Biotech’s only commercial product—breast cancer drug Nerlynx—still need improvement, company chief Alan Auerbach acknowledged. But as one analyst sees it, a label expansion may not even be enough to save the struggling med amid increased competition from drugs
read moreFor the second time this month, Gilead has suffered a setback in its public patent dispute with the U.S. government. A patient review board decided against striking up a review of HHS patents on HIV prevention drug Truvada after Gilead
read moreWith CGRP drugs on the rise in the preventive migraine market, old stalwarts like Allergan’s Botox are feeling the pinch from the new competition. But a new survey says neurologists may not be so quick to give up on Botox––and
read moreThe results represent the longest follow-up with any immuno-oncology–based therapy in previously untreated RCC patients. More: Opdivo/Yervoy continues to impress in kidney cancer Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals